(VIANEWS) – Shares of Alnylam Pharmaceuticals (NASDAQ Composite: ALNY) fell by a staggering 15.18% to $162.14 at 11:35 EST on Tuesday, following the last session’s upward trend. NASDAQ Composite is jumping 1.39% to $15,448.12, after three consecutive sessions in a row of gains. This seems, up to now, an all-around bullish trend exchanging session today.
Alnylam Pharmaceuticals’s last close was $166.36, 21.53% below its 52-week high of $212.00.
Today’s last reported volume for Alnylam Pharmaceuticals is 2766395 which is 348.8% above its average volume of 616393.
Alnylam Pharmaceuticals’s Sales
Alnylam Pharmaceuticals’s sales growth is 74.6% for the present quarter and 46.7% for the next. The company’s growth estimates for the ongoing quarter and the next is 28% and 23.9%, respectively.
Alnylam Pharmaceuticals’s Revenue
Year-on-year quarterly revenue growth grew by 112.1%, now sitting on 687.53M for the twelve trailing months.
Alnylam Pharmaceuticals’s last week, last month’s, and last quarter’s current volatility was a negative 7.65%, a negative 1.05%, and a positive 2.07%, respectively.
Alnylam Pharmaceuticals’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 7.65% (last week), 2.12% (last month), and 2.07% (last quarter), respectively.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,
Alnylam Pharmaceuticals’s stock is considered to be overbought (>=80).
Alnylam Pharmaceuticals’s Stock Yearly Top and Bottom Value
Alnylam Pharmaceuticals’s stock is valued at $162.14 at 11:35 EST, way below its 52-week high of $212.00 and way above its 52-week low of $120.83.
Alnylam Pharmaceuticals’s Moving Average
Alnylam Pharmaceuticals’s worth is way below its 50-day moving average of $192.23 and under its 200-day moving average of $173.76.
More news about Alnylam Pharmaceuticals (ALNY).